Loading...
NPI 1477157725 · Monrovia, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Universal Genetics LLC is a clinical medical laboratory provider located in Monrovia, California. This profile covers 1 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Universal Genetics LLC |
| Address | 604 E Huntington Dr Ste A |
| City | Monrovia |
| State | CA |
| ZIP | 91016 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 27, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $15.1M |
| Medicaid | $180.7K |
This provider’s payer mix is heavily weighted toward Medicare: reported lifetime Medicare revenue is $15.1M compared with $180.7K in Medicaid, indicating Medicare-driven scale and that the provider is effectively a single-payer (Medicare) revenue leader. The Medicaid footprint exists but is orders of magnitude smaller and likely supports a different set of testing services.
Medicare revenue is extremely concentrated: the precomputed top 3 Medicare codes account for 100.0% of Medicare revenue, and a single code, K1034, generates $15.4M (1.3M claims, $12 avg paid/claim) which equals 100.0% of the provider’s Medicare revenue. This concentration implies the provider’s Medicare business is almost entirely tied to provision of nonprescription self-administered COVID-19 tests as captured by K1034.
Medicaid revenue is also concentrated but less so: the top 3 Medicaid codes account for 89.4% of Medicaid revenue. The leading Medicaid contributors are 87636 ($71.8K, 39.7% of Medicaid revenue), U0004 ($62.3K, 34.4%), and G2023 ($27.7K, 15.3%), which together describe multiplex respiratory NAAT testing, high-throughput SARS-CoV-2 testing, and specimen collection operations.
On national competitive standing for Medicare K1034, the provider ranks #31 of 30,143 providers and is labeled an "extreme outlier" at the 100th percentile, meaning it bills far above typical national volume for this code. This ranking positions the provider as a dominant national participant for K1034-driven Medicare activity and suggests unusually large-scale processing or distribution tied to that single code.
By contrast, the provider’s Medicaid ranking by code shows mostly middling in-state participation for traditional lab codes: 87636 ranks #131 of 276 (53th percentile), U0004 ranks #63 of 147 (58th percentile), and G2023 ranks #166 of 497 (67th percentile), each characterized as typical, unremarkable volume in-state. Notably, K1034 on Medicaid ranks #5 of 51 (92th percentile) — high relative placement within the narrower in-state panel but still described in the source as typical volume for that code.
Operationally, the combined code mix suggests two related but distinct service lines: an outsized Medicare-facing operation focused on provisioning/claiming for nonprescription self‑administered COVID-19 tests (K1034), and a Medicaid-facing laboratory function performing multiplex NAAT diagnostics and specimen collection (87636, U0004, G2023). Analysts should interpret the business as a clinical medical laboratory that also appears to have built substantial scale around distribution and claims for over-the-counter COVID-19 test products.
The provider’s revenue concentration creates material sensitivity to policy or reimbursement changes for its top codes: with 100.0% of Medicare revenue tied to the top 3 Medicare codes and 89.4% of Medicaid revenue tied to the top 3 Medicaid codes, any contraction in coverage or price for those codes would disproportionately affect overall revenue. This concentration risk suggests analysts should monitor coding/payment policy changes for K1034 and the listed NAAT/testing codes.
The provider’s enrollment date (NPI enumerated 2020-11-27, ~6 years ago) indicates it became active during the COVID-19 era, consistent with the code mix dominated by SARS-CoV-2 testing and self‑test provisioning. Given that tenure, the revenue profile appears to reflect rapid scale-up in pandemic-era testing services rather than a long-established, diversified laboratory portfolio.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,284,780 | $10 | $15.4M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 2 | 2,780 | 710 | $10 | $58.8K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 820 | $90 | $71.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1,090 | $60 | $62.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,730 | $20 | $27.7K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,290 | $10 | $13.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 460 | $10 | $5.5K |
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 63 | 150 | 580 | $60 | $608.7K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 131 | 280 | 730 | $90 | $315.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 166 | 500 | 530 | $20 | $128.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 264 | 520 | 470 | $10 | $116K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 5 | 50 | 120 | $1 | $3.4K |
Other providers in the same ZIP code as Universal Genetics LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Dream Big Children's Services | CA | Community/Behavioral Health Agency | $0 | $25.3M |
| Laboratory Corporation Of America | CA | Clinical Medical Laboratory | $1.1M | $13.1M |
| Magic Owl Laboratories Inc. | CA | Clinical Medical Laboratory | $392K | $572K |
| Melanie Bennett | CA | Clinical Psychologist | $258.6K | $0 |
| Vartan Vartanians | CA | Diagnostic Radiology Physician | $129.6K | $0 |
| Anthony Cecere | CA | Psychologist | $114.6K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.